Loss of Expression of Reprimo, a p53-induced Cell Cycle Arrest Gene, Correlates with Invasive Stage of Tumor Progression and p73 Expression in Gastric Cancer
Author
dc.contributor.author
Saavedra, Kathleen
Author
dc.contributor.author
Valbuena, José
Author
dc.contributor.author
Olivares, Wilda
Author
dc.contributor.author
Marchant, María José
Author
dc.contributor.author
Rodríguez, Andrés
Author
dc.contributor.author
Torres Estay, Verónica
Author
dc.contributor.author
Carrasco Avino, Gonzalo
Author
dc.contributor.author
Guzmán, Leda
Author
dc.contributor.author
Aguayo González, Francisco
Author
dc.contributor.author
Roa, Juan Carlos
Author
dc.contributor.author
Corvalán, Alejandro H.
Admission date
dc.date.accessioned
2015-09-28T13:33:10Z
Available date
dc.date.available
2015-09-28T13:33:10Z
Publication date
dc.date.issued
2015
Cita de ítem
dc.identifier.citation
PLoS ONE 10(5): e0125834 May 8, 2015
en_US
Identifier
dc.identifier.other
DOI: 10.1371/journal.pone.0125834
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/133894
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Reprimo (RPRM), a downstream effector of p53-induced cell cycle arrest at G2/M, has been proposed as a putative tumor suppressor gene (TSG) and as a potential biomarker for non-invasive detection of gastric cancer (GC). The aim of this study was to evaluate the epigenetic silencing of RPRM gene by promoter methylation and its tumor suppressor function in GC cell lines. Furthermore, clinical significance of RPRM protein product and its association with p53/p73 tumor suppressor protein family was explored. Epigenetic silencing of RPRM gene by promoter methylation was evaluated in four GC cell lines. Protein expression of RPRM was evaluated in 20 tumor and non-tumor matched cases. The clinical significance of RPRM association with p53/p73 tumor suppressor protein family was assessed in 114 GC cases. Tumor suppressor function was examined through functional assays. RPRM gene expression was negatively correlated with promoter methylation (Spearman rank r = -1; p = 0.042). RPRM overexpression inhibited colony formation and anchorage-independent growth. In clinical samples, RPRM gene protein expression was detected in 75% (15/20) of non-tumor adjacent mucosa, but only in 25% (5/20) of gastric tumor tissues (p = 0.001). Clinicopathological correlations of loss of RPRM expression were significantly associated with invasive stage of GC (stage I to II-IV, p = 0.02) and a positive association between RPRM and p73 gene protein product expression was found (p<0.0001 and kappa value = 0.363). In conclusion, epigenetic silencing of RPRM gene by promoter methylation is associated with loss of RPRM expression. Functional assays suggest that RPRM behaves as a TSG. Loss of expression of RPRM gene protein product is associated with the invasive stage of GC. Positive association between RPRM and p73 expression suggest that other members of the p53 gene family may participate in the regulation of RPRM expression.
en_US
Patrocinador
dc.description.sponsorship
CONICYT-FONDECYT from the Government of Chile
1111014
CONICYT-FONDAP from the Government of Chile
15130011
Loss of Expression of Reprimo, a p53-induced Cell Cycle Arrest Gene, Correlates with Invasive Stage of Tumor Progression and p73 Expression in Gastric Cancer